A 12-week placebo-controlled trial of an amla-and-guduchi supplement for adult acne: what the null result means and what it doesn’t.
A clear-eyed look at which herbal acne remedies have real trial data, how thin that data is, and which carry documented liver or skin risks.
A 2026 placebo-controlled trial of an oral nelli-and-rasakinda formulation missed its lesion-count endpoint — and excluded most hormonally treated adults.
What a modest 2026 tea tree oil result does and doesn’t prove, plus the oxidation and oral-supplement risks the trials never measured.
A 2026 trial showed a trend toward fewer acne lesions but missed statistical significance—reminding us that trends aren’t proof and headlines can overstate preliminary results.
Learn how to weigh limited herbal-acne studies against established treatments, product safety concerns, and signs that need medical care.
The 2026 trial offers useful context for weighing LNSA against established acne treatments, including its limits and liver-safety concerns.
Learn how to judge limited herbal acne evidence, track results, and recognize when irritation or supplement risks require action.
Learn what the 2026 acne trial proved, what it did not, and why Tinospora calls for liver-safety monitoring.
Learn how to question herbal acne evidence, interpret safety claims, and compare botanical products with established care.
